Status:
WITHDRAWN
Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk
Lead Sponsor:
Texas Cardiac Arrhythmia Research Foundation
Conditions:
COVID-19
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Few studies have reported the efficacy of HCQ in reducing the viral load and improving the severity of symptoms in hospitalized COVID-19 cases with serious respiratory infection. However, the prophyla...
Detailed Description
This study is designed to evaluate the prophylactic efficacy of HCQ in COVID-19 cases with mild to moderate symptoms and in the hospital staff engaged in attending infected patients.
Eligibility Criteria
Inclusion
- Male or female over 18 years of age at the time of enrollment
- COVID-19 test positive patients with mild-moderate symptoms including fever \>37.50 F
- Consecutive consenting staff at ICU, ER and COVID-19 unit that have never been diagnosed with COVID-19
Exclusion
- Exclusion criteria:
- Hepatic cirrhosis or active hepatitis B or C
- Severe renal disease
- Hospitalized for severe symptoms of COVID-19 (ARDS), on mechanical ventilation or ECMO
- Contraindication to HCQ
- Using HCQ for some other condition (i.e. SLE, rheumatoid arthritis)
- Pregnant or breast feeding
- Known history of long QT syndrome (QTc \>500 ms on electrocardiogram)
- Seizure disorder
- Body weight \<50kg
- Psoriasis
- Unwilling to provide informed consent
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04371926
Start Date
June 1 2020
End Date
July 1 2021
Last Update
June 4 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.